Next Article in Journal
The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa
Previous Article in Journal
Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
Open AccessReview

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies

1
Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Torino, 10123 Torino, Italy
2
Division of Hematology 1U, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, 10126 Torino, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(9), 288; https://doi.org/10.3390/jcm7090288
Received: 23 August 2018 / Revised: 10 September 2018 / Accepted: 14 September 2018 / Published: 18 September 2018
(This article belongs to the Section Molecular Diagnostics)
The clearance of malignant clonal cells significantly correlates with clinical outcomes in many hematologic malignancies. Accurate and high throughput tools for minimal residual disease (MRD) detection are needed to overcome some drawbacks of standard molecular techniques; such novel tools have allowed for higher sensitivity analyses and more precise stratification of patients, based on molecular response to therapy. In this review, we depict the recently introduced digital PCR and next-generation sequencing technologies, describing their current application for MRD monitoring in lymphoproliferative disorders. Moreover, we illustrate the feasibility of these new technologies to test less invasive and more patient-friendly tissues sources, such as “liquid biopsy”. View Full-Text
Keywords: minimal residual disease; PCR; next generation sequencing; droplet digital PCR; circulating tumor DNA; lymphoma; leukemia; myeloma; lymphoproliferative diseases minimal residual disease; PCR; next generation sequencing; droplet digital PCR; circulating tumor DNA; lymphoma; leukemia; myeloma; lymphoproliferative diseases
Show Figures

Figure 1

MDPI and ACS Style

Dogliotti, I.; Drandi, D.; Genuardi, E.; Ferrero, S. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. J. Clin. Med. 2018, 7, 288.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop